Suchergebnisse - "Tonini, Giuseppe"

PubPharm (32)

1

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer : Phase III ERMES Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Pinto, C. | Orlandi, A. | Normanno, N. | +17

2

Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer : The PANDA Trial by the GONO Foundation

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Lonardi, S. | Rasola, C. | Lobefaro, R. | +70

3

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018)

enthalten in: BMC cancer | 2020

von Damato, A. | Iachetta, F. | Antonuzzo, L. | +10

4

Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients : the MOMA trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Cremolini, C. | Marmorino, F. | Bergamo, F. | +20

5

Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC

enthalten in: Future oncology (London, England) | 2018

von Pinto, C. | Normanno, N. | Orlandi, A. | +22

6

Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer : A Randomized Phase 2 Clinical Trial

enthalten in: JAMA oncology | 2018

von Cremolini, C. | Antoniotti, C. | Lonardi, S. | +22

7

The PANDA study : a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

enthalten in: BMC cancer | 2018

von Battaglin, F. | Schirripa, M. | Buggin, F. | +17

8

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer : A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest

enthalten in: European journal of cancer (Oxford, England : 1990) | 2017

von Cremolini, C. | Casagrande, M. | Loupakis, F. | +20

CommentIn: Eur J Cancer. 2017 Mar;73:71-73. - PMID 28081915

9

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer : updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

enthalten in: The Lancet. Oncology | 2015

von Cremolini, C. | Loupakis, F. | Antoniotti, C. | +17

CommentIn: Lancet Oncol. 2015 Dec;16(16):e577. - PMID 26678195

10

Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen : a single institution experience

enthalten in: Expert review of anticancer therapy | 2015

von Vincenzi, B. | Imperatori, M. | Picardi, A. | +6